Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kathy Ordoñez, Jay Shendure, Ivan Trifunovich, Federica DiPalma

Premium

RainDance Technologies has appointed Kathy Ordoñez to its board of directors. She is senior vice president at Quest Diagnostics, and was previously CEO of Celera. She also held several senior positions at Hoffmann La-Roche and oversaw the formation of Roche Molecular Systems, where she served as president and CEO.


The Hudson Alpha Institute for Biotechnology has awarded Jay Shendure its HudsonAlpha Life Sciences Prize for his work in the development and application of genomic technology, including completing a detailed sequence of DNA from HeLa cells. Shendure will receive the award for early career scientists on November 19. Shendure is an associate professor in the department of genome sciences at the University of Washington.


WaferGen Biosystems' board of directors has appointed President and CEO Ivan Trifunovich to the additional post of chairman of the board. He replaces Alnoor Shivji, who has been chairman since 2002 and has resigned to focus on a new startup venture. WaferGen said Joel Kanter, who has been a director since 2007, will serve as lead independent director.


The UK's Genome Analysis Center has appointed Federica DiPalma to director of science, where she will be responsible for all aspects of TGAC's scientific strategy and vision. Previously, she was head of vertebrate and health genomics at TGAC and prior to joining TGAC, she was assistant director of vertebrate biology at the Broad Institute.

The Scan

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.